Modelling of blood pressure outcomes in patients with and without established cardiovascular or renal disease following treatment with valsartan (the PREVIEW study)  by MacDonald, Karen et al.
AC
M
w
d
P
M
m
P
D
S
W
1
hrchives of Cardiovascular Disease (2013) 106, 124—134
Available  online  at
www.sciencedirect.com
LINICAL RESEARCH
odelling  of  blood  pressure  outcomes  in  patients
ith  and  without  established  cardiovascular  or  renal
isease  following  treatment  with  valsartan  (the
REVIEW  study)
odélisation  des  résultats  de  pression  artérielle  chez  les  patients  avec  et  sans
aladie  cardiovasculaire  ou  rénale  établie  traités  par  valsartan  (l’étude
REVIEW)
Karen  MacDonalda,  Heidi  Briéb,
Stefaan  Vancayzeeleb,  Christopher  Leea,c,d,
John  Bowlesa,  Kathleen  Piotrowskia,
Christine  Hermansb,  Ivo  Abrahama,c,∗
a Matrix45,  Tucson,  AZ,  USA
b Novartis  Pharma,  Vilvoorde,  Belgium
c Center  for  Health  Outcomes  and  PharmacoEconomic  Research,  University  of  Arizona  College
of Pharmacy,  Tucson,  AZ,  USA
d Oregon  Health  and  Science  University  School  of  Nursing,  Portland,  OR,  USA
Received  3  May  2012;  received  in  revised  form  22  November  2012;  accepted  27  November  2012
Available online  26  March  2013
KEYWORDS
Effectiveness;
Summary
Background.  —  Hypertensive  patients  with  established  cardiovascular  or  renal  disease  (ECVRD)Hypertension;
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Cardiovascular
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have an  added  10-year  risk  of  cardiovascular  events,  classiﬁed  by  the  European  Society  of
Hypertension/European  Society  of  Cardiology  as  ‘very  high’.
Aims. —  To  identify  determinants  of  blood  pressure  (BP)  outcomes  in  hypertensive  patients  with
and without  ECVRD  treated  in  second-line  with  valsartan.
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BP, blood pressure; CI, conﬁdence interval;
BP, diastolic blood pressure; ECVRD, established cardiovascular and/or renal disease; ESC, European Society of Cardiology; ESH, European
ociety of Hypertension; GP, general practitioner; ICC, intraclass correlation coefﬁcient; SBP, systolic blood pressure.
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Methods.  —  This  was  a  subgroup  analysis  comparing  patients  with  and  without  ECVRD  who
participated  in  the  PREVIEW  study,  a  90-day  observational  prospective  effectiveness  study  of
valsartan, conducted  in  Belgium.  Two-level  (patients  ‘nested’  under  physicians)  hierarchical
linear and  logistic  modelling  of  BP  values  and  BP  control  (140/90  mmHg;  130/80  mmHg  for  dia-
betics) at  90  days  was  applied  to  data  from  1107  patients  with  and  2087  patients  without  ECVRD
treated with  valsartan  by  504  general  practitioners.
Results.  —  Absolute  reductions  in  BP  were  similar  across  subgroups,  with  minor  variations  in
actual BP  levels  in  general  and  by  subgroup.  Fewer  patients  with  versus  without  ECVRD  achieved
targets for  systolic  BP,  diastolic  BP  and  combined  systolic/diastolic  BP  control.  Variability  in  BP
values and  control  at  90  days  attributable  to  a  physician-level  class  effect  ranged  from  24.6%  to
28.1% and  15.0%  to  22.4%,  respectively.  Physician-  and  patient-related  determinants  of  90-day
BP outcomes  varied  considerably  between  the  two  subgroups.
Conclusion.  —  Several  determinants  of  BP  outcomes  were  identiﬁed  comparing  patients  with  and
without ECVRD,  including  amenable  physician-level  and  patient-level  factors  and  warning  signs
for continued  risk  of  uncontrolled  BP.  ECVRD  patients  present  with  differential  characteristics,
conditions  and  determinants  that  mandate  individualized  attention  to  complement  general
evidence-based  antihypertensive  treatment.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Justiﬁcation.  —  Les  patients  hypertendus  ayant  une  atteinte  cardiovasculaire  ou  rénale  ont  une
augmentation  du  risque  d’évènement  cardiovasculaire  à  dix  ans,  considérée  comme  élevée  dans
la classiﬁcation  de  l’European  Society  of  Hypertension/European  Society  of  Cardiology.
Objectifs.  — Identiﬁer  les  déterminants  de  la  pression  artérielle  chez  les  patients  hypertendus,
avec ou  sans  attente  rénale  ou  cardiovasculaire,  traités  en  seconde  intention  par  valsartan.
Méthode.  — Cette  étude  est  une  analyse  en  sous-groupes  de  l’étude  PREVIEW,  comparant  des
patients  avec  et  sans  atteinte  rénale  et  cardiovasculaire  participant  à  cette  étude,  avec  une
période d’observation  de  90  jours,  effectuée  en  Belgique.  Un  modèle  linéaire  hiérarchisé  a  deux
niveaux :  patients  et  médecins  ainsi  qu’un  modèle  logistique  de  valeurs  des  pressions  artérielles
et de  son  contrôle  (140/90  mmHg  ;  130/80  mmHg  chez  les  diabétiques)  ont  été  appliqués  à
90 jours,  parmi  les  1107  patients  avec  et  2087  patients  sans  atteinte  rénale  ou  cardiovasculaire
traités  par  valsartan  par  504  médecins  généralistes.
Résultats.  — La  réduction  absolue  de  la  pression  artérielle  était  similaire  dans  les  différents
sous-groupes  avec  des  variations  mineures  de  niveaux  de  pression  artérielle,  tant  dans  la  popu-
lation générale  que  dans  l’analyse  en  sous-groupes.  Un  nombre  moindre  de  patients,  avec  versus
sans atteinte  rénale  ou  cardiovasculaire,  a  atteint  les  objectifs  cibles  de  niveau  de  pression
artérielle systolique,  diastolique  ainsi  que  l’association  des  deux.  La  variabilité  dans  les  valeurs
de pression  artérielle  à  90  jours  attribuable  à  l’effet  médecin  variait  de  24,6  à  28,1  %  et  de  15  %
à 22,4  %,  respectivement.  Les  déterminants  liés  aux  patients  ou  aux  médecins  de  l’objectif  de
pression artérielle  à  90  jours  variaient  de  fac¸on  signiﬁcative  entre  les  deux  sous-groupes.
Conclusion.  —  De  nombreux  déterminants  de  l’évolution  de  la  pression  artérielle  ont  été  identi-
ﬁés chez  des  patients  avec  et  sans  atteinte  rénale  et  cardiovasculaire  prenant  en  considération
des facteurs  liés  aux  médecins  et  aux  patients,  ainsi  que  la  prise  en  compte  de  signes  d’alerte
pour un  contrôle  des  niveaux  de  pression  artérielle.  Les  patients  ayant  une  atteinte  rénale  ou
cardiovasculaire  avaient  des  caractéristiques  différentes  et  des  déterminants  également  dif-
férents, justiﬁant  une  approche  individualisée  pour  compléter  le  traitement  antihypertenseur
en fonction  de  la  présence  ou  de  l’absence  de  ce  retentissement  rénal  ou  cardiovasculaire.
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Background
Cardiovascular  disease  resulting  from  poor  blood  pressure
(BP)  control  is  a  leading  cause  of  death  globally  [1,2].
Up  to  13.5%  of  premature  deaths  —  or  7.6  million  deaths
worldwide  annually  —  are  attributed  to  suboptimal  con-
trol  of  arterial  hypertension  [3,4]. Europeans  are  among
those  with  the  highest  systolic  BP  (SBP)  in  the  world  and
thus  are  at  higher  risk  of  end-organ  damage  [5].  Achieving
h
d
is  droits  réservés.
uideline-recommended  BP  targets  [6,7]  is  difﬁcult  in  gen-
ral  [8—10]  and  an  even  greater  challenge  in  patients  with
stablished  cardiovascular  and/or  renal  disease  (ECVRD)
6—8].  The  European  Society  of  Hypertension/European
ociety  of  Cardiology  (ESH/ESC)  guidelines  for  the  manage-
ent  of  hypertension  [11,12]  classify  patients  with  ECVRD  as
aving  a  ‘very  high  added’  10-year  risk  for  (additional)  car-
iovascular  events.  Identifying  determinants  of  BP  outcomes
n  patients  with  ECVRD  and  how  these  may  be  different
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rom  those  in  patients  without  ECVRD  is  critical  to  effec-
ive  hypertension  management  and  prevention  of  further
ardiovascular  and  renal  disease.
We  report  here  on  subgroup  analyses  for  1107  patients
ith  and  2087  patients  without  ECVRD  who  were  included
n  the  Belgian  PREVIEW  study  by  504  general  practitioners
GPs)  [13]. PREVIEW  was  a  prospective  pharmacoepidemio-
ogical  multicentre  study  that  examined  determinants  and
redictors  of  BP  reduction  and  control  following  90-day
econd-line  treatment  with  the  angiotensin  II  receptor
locker  (ARB)  valsartan.  The  purpose  of  the  subgroup
nalyses  was  fourfold:  to  examine  whether  there  were
igniﬁcant  differences  in  patient  characteristics,  antihyper-
ensive  treatment  and  BP  values  and  control  at  90  days  in
atients  with  and  without  ECVRD;  to  quantify  the  propor-
ions  of  variance  in  BP  outcomes  at  90  days  attributable
o  physician-level  versus  patient-level  factors;  to  identify
he  multilevel  (patients  ‘nested’)  determinants  of  BP  values
t  90  days  in  these  two  subsamples;  and  to  identify  inde-
endent  predictors  of  uncontrolled  BP  at  90  days  in  both
ubsamples.
ethods
he  methodology  of  the  PREVIEW  study  is  described  in  detail
n  the  article  reporting  the  results  for  the  entire  sample,
s  are  data  on  the  physician  sample,  including  knowledge
f  and  practice  according  to  evidence-based  hypertension
uidelines  [13]. Elements  of  relevance  are  summarized
elow.
esign
REVIEW  was  designed  as  a  90-day  prospective  multicentre
ultilevel  (patients  ‘nested’  under  physicians)  pharma-
oepidemiological  study  of  the  effectiveness  of  valsartan-
entric  antihypertensive  regimens  and  the  determinants
hereof,  in  patients  in  whom  prior  treatment  had  failed  or
as  not  tolerated.  A  total  of  3194  hypertensive  patients
SBP  ≥  140  mmHg  and/or  DBP  ≥  90  mmHg;  SBP  ≥  130  mmHg
nd/or  DBP  ≥  80  mmHg  for  diabetic  patients)  treated  by
04  general  practitioners  in  Belgium  were  started  on  a
alsartan-centric  regimen  in  accordance  with  their  physi-
ian’s  best  clinical  judgment  and  re-evaluated  90  days
ater.
amples for  subgroup analyses
atients  were  considered  to  have  ECVRD  if  they  pre-
ented  at  baseline  with  at  least  one  of  the  following
ardiovascular  and/or  renal  conditions  comorbid  to  their
rterial  hypertension:  myocardial  infarction;  angina  pec-
oris;  coronary  revascularization;  heart  failure;  ischaemic  or
aemorrhagic  cerebrovascular  accident;  transient  ischaemic
ttacks;  intermittent  claudication;  peripheral  bypass/stent
r  amputation;  or  diabetic  nephropathy  or  any  other
ephropathies  as  evidenced  by  creatinine  greater  or  equal
o  1.5  mg/dL  and/or  proteinuria.  The  subsamples  consisted
f  patients  whose  treating  physician  had  decided  inde-
endently,  according  to  best  clinical  judgment  and  within
he  approved  label  and  reimbursement  regulations,  to
a
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rescribe  one  of  three  formulations  of  valsartan  (80  mg,
60  mg  or  80  mg/12.5  mg  hydrochlorothiazide)  as  second-
ine  monotherapy  or  combination  therapy  because  ﬁrst-line
herapy  had  failed  or  was  not  tolerated.  Patients  with  known
ensitivity  to  ARBs  or  hydrochlorothiazide  were  excluded,  as
ere  patients  concomitantly  treated  with  an  ARB  other  than
alsartan.
ata model
hysician  questionnaire
he  physician  questionnaire  comprised:  practice  type,
ocation/setting  and  patient  mix;  demographics;  sources
f  information  and  knowledge  related  to  hypertension;
ypertension  management  practices;  prescription  pat-
erns;  management  of  adverse  effects;  SBP/DBP  thresholds
or  treatment  initiation  and  intensiﬁcation;  percep-
ions  of  patient  adherence;  and  knowledge  of  practice
uidelines.
aseline  patient  data
he  baseline  patient  data  acquired  were  as  follows:
emographics;  hypertension  and  cardiovascular  history;
omorbidities;  lifestyle;  prior  antihypertensive  medications;
BP  and  DBP;  clinical  data;  starting  valsartan  dose;  class  of
oncomitant  antihypertensives;  and  patient-reported  num-
er  of  days  they  had  been  non-adherent  in  the  preceding  4
eeks.
atient  follow-up  data
he  patient  follow-up  data  acquired  after  90  days  were  as
ollows:  SBP  and  DBP;  concomitant  drug(s)  taken  or  changed
ince  previous  visit;  clinical  data;  patient-reported  num-
er  of  days  they  had  been  non-adherent  in  the  preceding
 weeks;  changes  in  valsartan  dose  since  previous  visit;  and
dverse  effects  over  the  past  90  days.
GPs  were  asked  to  measure  BP  three  times  at  1  to  2-
in  intervals  in  a  sitting  position  after  5  min  of  rest  using  a
alibrated  standard  sphygmomanometer  and  appropriately-
ized  cuff  placed  at  heart  level  [14]. The  mean  of  the  three
itting  measurements  without  rounding  was  recorded  as  the
BP  and  DBP.
tatistical analysis
tandard  descriptive  statistics  were  used  to  describe  the
ubsamples,  including  proportions  and  appropriate  measures
f  central  tendency  and  dispersion.  Comparisons  between
ubsamples  were  made  using  independent  sample  t  tests,
orrected  as  necessary  for  unequal  variances,  or  Pearson’s
r  Yates’s  2 tests  (contingency  corrected)  or  Fisher’s  exact
est  where  appropriate.
We  hypothesized  that  BP  outcomes  in  each  subsam-
le  were  related  to  physician-  and  patient-level  variables.
ach  participating  physician  recruited  several  patients;
herefore  patients  could  not  be  considered  independent
ut  instead  ‘nested’  under  their  treating  physician.  We
ssumed  that  the  nj patients  recruited  by  physician  j
ight  share  some  proportion  of  variance  in  BP  values
ttributable  to  their  common  physician  and  that  this  physi-
ian’s  inﬂuence  might  impact  BP  values  prior  to  any
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patient-speciﬁc  variables.  Accordingly,  we  applied  two-level
hierarchical  linear  and  logistic  modelling  for  each  sub-
sample  [15]. The  intraclass  correlation  coefﬁcient  (ICC)
quantiﬁed  the  variability  in  patient  outcome  attributable
to  within-physician  variability  before  any  patient-level
determinants  were  considered.  Likelihood-ratio  tests  were
performed  to  determine  if  the  physician-level  ICC  was  sig-
niﬁcantly  greater  than  zero.  Adjusted  slope  coefﬁcients
or  odds  ratios  and  95%  conﬁdence  intervals  (CI)  were  cal-
culated  to  estimate  the  direction  and  strength  of  the
relationship  between  individual  factors  and  BP  values  and
control.  The  ESH/ESC  and  Seventh  Report  of  the  Joint
National  Committee  on  Prevention,  Detection,  Evaluation,
and  Treatment  of  High  Blood  Pressure  (JNC-7)  guidelines  for
BP  control  (140/90  mmHg  for  non-diabetics;  130/80  mmHg
for  diabetics)  [6,7]  were  used  to  determine  controlled
versus  uncontrolled  BP.  Statistical  signiﬁcance  was  set
at  P  <  0.05,  with  corrections  for  multiplicity  applied  as
necessary.
Results
Patient characteristics, medical history and
clinical status at baseline
Of  the  3194  patients  with  evaluable  data,  1107  (35.9%)
had  ECVRD  whereas  2087  (64.1%)  did  not.  Compared  with
patients  without  ECVRD,  patients  with  ECVRD  tended  to
be  older,  male  and  living  alone  (Table  1).  A  larger  pro-
portion  of  patients  with  ECVRD  had  signiﬁcant  risk  factors
at  baseline,  including  lack  of  physical  exercise,  dyslipi-
daemia,  diabetes,  elevated  C-reactive  protein  and  family
history  of  early  cardiovascular  disease.  These  patients  had
been  treated  for  hypertension  longer,  with  more  classes
of  antihypertensives  and  with  more  prior  antihypertensive
medication  changes.  Their  SBP  and  DBP  at  the  time  of  enroll-
ment  were  slightly  but  signiﬁcantly  lower  compared  with
patients  without  ECVRD.  Both  groups  had  statistically  sim-
ilar  proportions  of  patients  who  admitted  to  having  been
non-adherent  to  their  antihypertensive  medication  prior  to
enrolment  in  the  study.
Evolution of BP from baseline to follow-up
At  90  days,  mean  SBP  was  not  statistically  different  between
the  two  groups,  but  mean  DBP  was  lower  among  patients
with  ECVRD  (Table  2).  Mean  SBP  and  DBP  at  follow-
up  were  statistically  similar  between  diabetic  patients
with  and  without  ECVRD,  but  were  higher  among  non-
diabetic  patients  without  ECVRD.  Mean  absolute  changes
in  mmHg  from  baseline  to  follow-up  were  statistically  sim-
ilar  among  patients  with  and  without  ECVRD  in  general
and  stratiﬁed  by  diabetic  status.  BP  control  rates  at  base-
line  were  not  statistically  different  between  the  ECVRD
and  non-ECVRD  groups  in  general  and  stratiﬁed  by  dia-
betic  status.  At  follow-up,  the  proportions  of  patients  with
controlled  SBP,  DBP  and  combined  SBP/DBP  were  higher
among  patients  without  ECVRD  in  general,  although  these
differences  were  not  evident  when  stratiﬁed  by  diabetic
status.
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ttribution of variance to physician class
ffect
lood  pressure  values  at  90  days
mong  patients  with  ECVRD,  25.5%  of  the  variance  in  SBP
t  follow-up  was  attributable  to  a  physician  class  effect
ICC  0.255,  95%  CI  0.189—0.331;  P  <  0.001),  similar  to  that
bserved  for  patients  without  ECVRD  (ICC  0.257,  95%  CI
.212—0.306;  P  <  0.001).  The  corresponding  DBP  percent-
ges  of  attributable  variance  were  28.1%  for  patients  with
CVRD  (ICC  0.281,  95%  CI  0.214—0.35;  P  <  0.001)  and  24.6%
or  patients  without  ECVRD  (ICC  0.246,  95%  CI  0.202—0.295;
 <  0.001).
lood  pressure  control  at  90  days
mong  patients  with  ECVRD,  a  physician  class  effect
ccounted  for  20.7%  (ICC  0.207,  95%  CI  0.123—0.329;
 <  0.001)  and  19.8%  (ICC  0.198,  95%  CI  0.214—0.356;
 <  0.001)  of  the  variance  in  SBP  control  among  patients  with
nd  without  ECVRD,  respectively.  The  corresponding  per-
entages  for  DBP  were  15.0%  for  patients  with  ECVRD  (ICC
.150,  95%  CI  0.144—0.265;  P  <  0.001)  and  15.3%  for  patients
ithout  ECVRD  (ICC  0.153,  95%  CI  0.102—0.224;  P  <  0.001).
or  combined  SBP/DBP  control,  the  percentages  were  22.4%
ICC  0.224,  95%  CI  0.133—0.353;  P  <  0.001)  for  patients  with
CVRD  and  19.8%  (ICC  0.198,  95%  CI  0.143—0.267;  P  <  0.001)
or  patients  without  ECVRD.
odelling of blood pressure values and  control
t follow-up
able  3  presents  the  hierarchical  linear  models  for  SBP  and
BP  values  at  90  days  for  the  ECVRD  and  non-ECVRD  groups.
able  4  summarizes  the  hierarchical  logistic  models  for  SBP,
BP  and  combined  SBP/DBP  control  for  patients  with  and
ithout  ECVRD.  Table  5  summarizes  the  variables  retained  in
he  ﬁve  models  for  each  group,  indicating  whether  a  patient-
r  physician-related  determinant  increased  or  decreased
BP  or  DBP  at  90  days  or  increased  or  decreased  the  odds
f  uncontrolled  SBP,  DBP  and  combined  SBP/DBP  at  90  days,
tratiﬁed  by  ECVRD  status.
Patient-related  variables  retained  in  three  or  more
odels  included  age,  lack  of  regular  physical  exercise,  being
ighly  vulnerable  to  uncontrolled  BP,  concomitant  treat-
ent  with  a  -adrenergic  blocker  and  non-adherent  days
n  the  past  4  weeks.  Less  frequently  retained  variables
ncluded  living  alone,  obesity,  family  history  of  prema-
ure  cardiovascular  disease,  days  elapsed  since  most  recent
P  measurement,  C-reactive  protein  greater  or  equal  to
 mg/dL  and  being  treated  with  80  mg  valsartan  (versus
igher  doses)  and/or  an  angiotensin-converting  enzyme
nhibitor  concomitantly.  As  to  physician-related  variables,
ears  in  practice  and  the  number  of  clinical  practices
hat  were  concordant  with  best  practice  guidelines  were
ncluded  in  three  or  more  models;  this  refers  to  hyper-
ensive  treatment  practices  reported  by  physicians  that
ere  in  accordance  with  the  prevailing  ESH/ESC  guidelines.
etained  less  frequently  were  the  number  of  hypertension
atients  seen  in  the  past  12  months,  the  median  duration  of
he  ﬁrst  visit  with  a newly-diagnosed  hypertension  patient
r  a  visit  for  titrating  antihypertensive  medication  and  the
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Table  1  Baseline  patient  characteristics  stratiﬁed  by  ECVRDa.
With  ECVRD
(n  =  1107)
Without  ECVRD
(n  =  2087)
P
Age  (years) 69.1  ±  10.2  60.4  ±  11.5  <  0.001
Female  49.7  53.7  0.011
Living  alone  30.6  22.6  <  0.001
Race  0.256
White  97.7  98.1
Non-white 2.3 2.0
Risk  factors
Hypercholesterolaemia 63.7 53.9 <  0.001
Diabetes  mellitus 28.8  15.9  <  0.001
Smoker  25.8  29.9  0.008
Excess  alcohol  intake 16.8  17.1  0.435
Lack  of  regular  exercise 62.3 55.1  <  0.001
Obesity 43.5 45.2 0.197
Family  history  of  premature  cardiovascular  disease 19.9 15.9  0.003
C-reactive  protein  ≥  1  mg/dL 6.2 2.3 <  0.001
Total  cholesterol  mg/dL 217.1  ±  40.6 219.0  ±  39.3 0.220
HDL  mg/dL 55.2  ±  18.0 57.6  ±18.6 0.001
LDL  mg/dL 129.1  ±  35.7 131.3  ±  35.3 0.124
Hypertension  history
Years  on  hypertensive  therapy  6.9  ±  6.7  4.8  ±  5.7  <  0.001
Number  of  prior  antihypertensive  medication  switches  1.7  ±  1.6  1.2  ±  1.4  <  0.001
Number  of  prior  antihypertensive  classes  (of  six)  1.9  ±  0.9  1.6  ±  0.8  <  0.001
Not  adherent  with  antihypertensive  medications  at  baseline  36.7  35.0  0.190
SBP  at  enrollment  153.5  ±  16.0  154.9  ±  15.3  0.023
DBP  at  enrollment  90.4  ±  9.2  91.8  ±  9.2  <  0.001
Treatment  patterns
Valsartan  80  mg  12.8  13.7
0.022Valsartan  160  mg  68.8  71.8
Valsartan  80  mg  +  HCTZ  12.5  mg  18.4  14.6
Concomitant  diuretic  35.8  28.1  <  0.001
Concomitant  -adrenergic  blocker  36.2  27.2  <  0.001
Concomitant  calcium  antagonist  23.2  14.8  <  0.001
Concomitant  -adrenergic  blocker  3.9  1.9  0.001
Concomitant  ACE  inhibitor  4.8  2.0  <  0.001
Data are mean ± standard deviation or %. ACE: angiotensin-converting enzyme; ECVRD: established cardiovascular/renal disease; HDL:
high density lipoprotein; HCTZ: hydrochlorothiazide; LDL: low density lipoprotein; DBP: diastolic blood pressure; SBP: systolic blood
pressure. Note: cardiovascular/renal history indicates patients who have had one or more of the following: myocardial infarction; angina
pectoris; coronary revascularization; heart failure; ischaemic or haemorrhagic cerebrovascular accident; transient ischaemic attacks;
intermittent claudication; peripheral bypass/stent; amputation; diabetic nephropathy; renal impairment (creatinine > 1.5 mg/dL);
proteinuria; and/or advanced retinopathy.
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edian  number  of  visits  during  the  ﬁrst  3  months  following
iagnosis  of  hypertension  to  achieve  BP  control.
iscussion
his  subgroup  analysis  comparing  1107  patients  with  and
087  patients  without  ECVRD  yielded  ﬁve  principal  ﬁnd-
ngs.  First,  both  groups  had  different  proﬁles  in  terms
f  demographics,  cardiovascular  risk  factors,  hypertension
istory  and  past  and  current  antihypertensive  treatment,
E
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tndicating  that  ECVRD  is  a  clinically  relevant  differentiator
f  hypertensive  patient  mix.  Second,  as  to  BP  outcomes,
here  were  only  slight  differences  between  groups  in  BP
alues  at  90  days  and  absolute  change  in  BP  from  baseline
o  follow-up,  suggesting  that  BP  reduction  can  be  achieved
n  patients  with  and  without  ECVRD.  Third,  fewer  patients
ith  ECVRD  achieved  BP  targets  than  did  patients  without
CVRD;  hence,  ECVRD  can  be  considered  as  a  warning  signal
or  antihypertensive  treatment  failure.  Fourth,  physician-
evel  class  effects  explained  between  15.0%  and  28.1%  of
he  variance  in  BP  outcomes  before  patient-level  factors
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Table  2  BP  outcomes  at  90  days  stratiﬁed  by  ECVRD  status.
Patients  with  ECVRD  Patients  without  ECVRD
BP  values Absolute   BP  values Absolute  
SBP  (mmHg)
All  patients 138.7 ± 12.1  —14.8  ±  16.6  139.1 ±  11.9  —15.7  ±  15.9
Non-diabetics 138.2 ±  12.0  —15.7  ±  16.8  138.8 ±  11.8a —15.8  ±  15.7
Diabetics 139.6 ±  12.2  —12.6  ±  15.7  140.9 ±  12.6  —15.0  ±  16.8
DBP  (mmHg)
All  patients  82.3  ±  7.5  —8.2  ±  10.1  82.8  ±  7.3a —8.9  ±  9.9
Non-diabetics  82.0  ±  7.5  —8.6  ±  10.1  82.9  ±  7.3a —9.1  ±  9.9
Diabetics  82.7  ±  7.5  —7.4  ±  10.1  83.2  ±  7.4  —7.9  ±  10.1
Baseline  90  days  Baseline  90  days
SBP  controlled
All  patients  8.4  35.1  9.3  40.5a
Non-diabetics  10.9  44.9  10.6  46.7
Diabetics  2.2  11.0  2.5  7.8
DBP  controlled
All  patients  25.2  61.3  25.7  67.6a
Non-diabetics  33.0  78.7  29.7  77.4
Diabetics  5.8  18.8  4.9  15.9
SBP/DBP  controlled
All  patients 6.7  31.4  7.6  36.0a
Non-diabetics  9.2  42.3  8.8  42.2
Diabetics 0.3  1.2  4.9  3.1
Data are mean ± standard deviation or %. : change relative to baseline values; BP: blood pressure; DBP: diastolic blood pressure;
ECVRD: established cardiovascular/renal disease; SBP: systolic blood pressure.
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aa Indicates statistically signiﬁcant difference between groups (P v
were  considered;  this  conﬁrms  percentages  observed  in
other  studies  on  valsartan  that  we  have  conducted  [16].
Lastly,  despite  some  convergence,  the  multilevel  determi-
nants  of  BP  values  and  the  logistic  likelihood  of  BP  control
varied  considerably  between  hypertensive  patients  with
and  without  ECVRD;  this  underscores  that  antihypertensive
treatment  with  valsartan  should  carefully  consider  patient-
and  physician-related  variables  that  may  inﬂuence  differen-
tial  outcomes  in  patients  with  ECVRD.
Considering  that  patients  with  ECVRD  were  older,  more
likely  to  be  male,  had  a  higher  prevalence  of  most  risk
factors  and  all  indices  of  advanced  pathology,  had  been  diag-
nosed  with  hypertension  longer  and  had  more  complex  prior
antihypertensive  treatment  than  patients  without  ECVRD,  it
is  remarkable  that  only  5%  fewer  of  them  achieved  90-day
SBP  control  (35.1%  and  40.5%,  respectively)  and  combined
SBP  and  DBP  control  (31.4%  and  36.0%,  respectively)  than
patients  without  ECVRD.  Thus,  these  data  provide  evidence
of  the  effectiveness  of  valsartan  as  a  second-line  antihy-
pertensive  agent  in  patients  with  and  without  ECVRD.  The
results  may  also  be  due,  partially,  to  the  fact  that  more
patients  with  ECVRD  were  treated  with  each  class  of  con-
comitant  antihypertensive  agent  in  addition  to  valsartan
than  patients  without  ECVRD;  this  may  reﬂect  the  greater
antihypertensive  treatment  complexity  for  these  patients
than  for  patients  with  a  lower  global  cardiovascular  risk
[6,7,11].
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Several  determinants  of  SBP  and  DBP  values  and  predic-
ors  of  lack  of  SBP,  DBP  and  SBP/DBP  control  at  90  days  merit
urther  discussion.  These  determinants  fall  into  three  cat-
gories:  non-modiﬁable  variables,  manageable  conditions
nd  modiﬁable  risk  factors.  The  non-modiﬁable  variables
erve  an  important  alert  function.  In  addition  to  older  age
eing  associated  with  higher  SBP  but  lower  DBP,  hyperten-
ion  management  in  older  adults  is  characterized  by  an
ven  greater  sensitivity  to  severe  diabetes  (as  evidenced
y  advanced  retinopathy),  a  complexity  of  antihypertensive
egimens  used  in  attempts  to  bring  BP  under  control,  and
ardiovascular  risk  [17]. Sex  was  not  retained  as  a  determi-
ant  despite  other  evidence  that  BP  control  may  be  more
ifﬁcult  to  achieve  in  women  and  differences  in  determi-
ants  of  BP  outcomes  between  women  and  men  [18]. Living
lone  was  retained  in  one  model  and  may  refer  more  gener-
lly  to  a  lack  of  social  support  [19]. The  inﬂuence  of  a  family
istory  of  premature  cardiovascular  disease  on  BP  outcomes
nderscores  the  interaction  between  this  risk  factor  and
atients’  current  ECVRD.
Diabetes  had  the  single  most  inﬂuential  impact  on
P  outcomes  and  severely  compromises  the  likelihood  of
chieving  BP  control.  Baseline  variables  as  well  as  the
ariables  retained  in  the  models  point  more  broadly  at
he  negative  impact  of  metabolic  syndrome  on  BP  val-
es  and  BP  control,  especially  among  patients  with  ECVRD
ut  also  among  patients  without  ECVRD.  Diabetes  and
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Table  3  Hierarchical  linear  modelling  of  BP  values  at  90  days  by  ECVRD  status.
Patients  with  ECVRD  coefﬁcient  Patients  without  ECVRD  coefﬁcient
Estimate  Standard  error  P  Estimate  Standard  error  P
SBP
Intercept  130.321  2.763  0.001  134.210  1.632  <  0.001
Patient  age  0.095  0.036  0.009  0.077  0.023  0.001
Diabetes  1.864  0.707  0.008
Lack  of  regular  physical
exercise
2.709  0.784  0.001
Highly-vulnerable  patient
cluster
3.960  0.771  <  0.001  3.040  0.562  <  0.001
Concomitant  -adrenergic
blocker
1.535  0.617  0.013
Non-adherent  days  in  past
4  weeks
1.876 0.572  0.001
GP:  hypertension  patients
seen  in  past  12  months
—0.003 0.002  0.047
GP:  number  of
BPG-concordant  practices
—0.176  0.080  0.025  —0.149  0.058  0.011
DBP
Intercept  78.008  1.249  <  0.001  81.673  1.333  <  0.001
Patient  age  —0.051  0.014  <  0.001
Obesity  1.140  0.461  0.014  0.779  0.337  0.021
Lack  of  regular  physical
exercise
—0.684  0.353  0.053
Family  history  of
premature  ECVRD
1.177  0.594  0.048
Highly-vulnerable  patient
cluster
1.657  0.475  0.001  1.371  0.341  <  0.001
Valsartan  80  mga —2.242  0.859  0.009
Valsartan  160  mga —0.694  0.621  0.264
Concomitant  ACE  inhibitor 3.484  1.126  0.002
Concomitant  ß-adrenergic
blocker
1.377  0.273  <  0.001
Non-adherent  in  the  past  4
weeks
1.812  0.503  <  0.001  1.107  0.347  0.001
GP:  years  in  practice  0.070  0.026  0.008
GP:  median  duration  of
ﬁrst  visit  for
newly-diagnosed
hypertensive  patient
0.142 0.056  0.012  0.085  0.042  0.044
ACE: angiotensin-converting enzyme; BP: blood pressure; BPG: best practice guidelines; DBP: diastolic blood pressure; ECVRD: established
cardiovascular/renal disease; GP: general practitioner; SBP: systolic blood pressure.
a Referent is valsartan 80 mg/hydrochlorothiazide 12.5 mg.
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petabolic  syndrome  are  manageable  conditions  and  our
ndings  underscore  the  importance  of  aggressive  diabetes
reatment  but  also,  more  comprehensively,  the  constituent
lements  of  metabolic  syndrome  (weight,  lipids  and  blood
ressure)  and  their  associated  risk  factors  [20]. Relat-
dly,  ﬁtting  the  heuristic  proﬁle  of  high  vulnerability  to
ncontrolled  hypertension  [21]  was  consistently  associ-
ted  with  increased  BP  values  and  decreased  BP  control,
he  effects  being  more  pronounced  among  patients  with
CVRD.
The  modiﬁable  variables  found  to  impact  on  BP
utcomes,  especially  among  patients  with  ECVRD,  are
a
c
p
Aehavioural.  Exercise  regimens  must  be  developed  for
atients  under  consideration  of  whether  or  not  they  have
CVRD,  to  optimize  the  BP-lowering  effect  of  physical  activ-
ty  [22—24]. Low  adherence  decreases  the  outcomes  of
edication  treatment  by  26%.  Our  subanalyses  underscore
ow  BP  values  rise  and  BP  control  declines  for  every  day
f  non-adherence  in  the  preceding  4  weeks.  GPs  must  be
rovided  with  rapid  if  not  intuitive  methods  of  assessing
dherence  that  can  be  integrated  seamlessly  into  the  clini-
al  visit  and  patients  must  be  counselled  to  be  adherent  and
rovided  with  tools  enabling  better  medication  behaviour.
 known  determinant  of  non-adherence  is  the  complexity
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Table  4  Hierarchical  logistic  modelling  of  uncontrolled  BP  at  90  days  by  ECVRD  status.
Patients  with  ECVRD  Patients  without  ECVRD
OR  95  %  CI  P  OR  95  %  CI  P
Uncontrolled  SBP  at  90  days
Patient  age  1.017  1.002—1.033  0.027  1.013  1.003—1.023  0.008
Lack  of  regular  physical  exercise  1.686  1.226—2.319  0.001
Diabetes  7.636  4.835—12.061  <  0.001  14.690  8.601—25.091  <  0.001
C-reactive  protein  ≥  1  mg/dL  0.515  0.271—0.982  0.044
Highly-vulnerable  patient  cluster  1.849  1.330—2.571  <  0.001  1.565  1.241—1.973  <  0.001
Concomitant  ß-adrenergic
blocker
1.282 1.006—1.633  0.044
Non-adherent  days  in  past  4
weeks
1.349 1.069—1.703 0.012
GP:  years  in  practice  1.026  1.008—1.045  0.006
GP:  median  duration  of  visits  for
antihypertensive  medication
titration  (min)
1.058 1.017—1.102  0.005
GP:  number  of  BPG-concordant
practices
0.975 0.958—0.993 0.005
Uncontrolled  DBP  at  90  days
Patient  age  0.981  0.970—0.992  0.001
Lives  alone  1.510  1.045—2.183  0.028
Diabetes  15.577  10.534—23.035  <  0.001  25.079  17.102—36.777  <  0.001
Highly-vulnerable  patient  cluster  1.492  1.051—2.117  0.025  1.810  1.410—2.324  <  0.001
Concomitant  ACE  inhibitor  3.461  1.528—7.841  0.003
Concomitant  ß-adrenergic
blocker
1.393 1.059—1.832  0.018
Non-adherent  days  in  past  4
weeks
1.690 1.180—2.421  0.004  1.310  1.001—1.713  0.049
GP:  hypertension  patients  seen
in  past  12  months
0.999 0.999—1.000  0.044
GP:  mean  number  of  visits  during
ﬁrst  3  months  to  achieve  BP
control
0.968 0.940—0.999  0.035
GP:  number  of  BPG-concordant
practices
0.971  0.944—0.999  0.046  0.959  0.939—0.980  <  0.001
Uncontrolled  SBP  and  DBP  at  90
days
Lack  of  regular  exercise  1.719  1.235—2.393  0.001
Diabetes  14.815  8.030—27.332  <  0.001  41.309  16.89—101.04  <  0.001
Highly-vulnerable  patient  cluster  2.086  1.477—2.948  <  0.001  1.696  1.335—2.154  <  0.001
Days  since  most  recent  BP
measurement
1.002 1.000—1.003  0.047
Non-adherent  days  in  past  4
weeks
1.116 1.026—1.214  0.011
GP:  years  in  practice  1.020  1.001—1.040  0.039  1.015  1.001—1.028  0.030
GP:  median  duration  of  visits  for
antihypertensive  medication
titration  (min)
1.082 1.037—1.129  <  0.001
GP:  number  of  BPG-concordant
practices
0.970 0.952—0.987  0.001
ACE: angiotensin-converting enzyme; BP: blood pressure; BPG: best practice guidelines; CI: conﬁdence interval; DBP: mean sitting
diastolic blood pressure; ECVRD: established cardiovascular/renal disease; GP: general practitioner; OR: adjusted odds ratio; SBP: mean
sitting systolic blood pressure.
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Table  5  Signiﬁcant  determinants  of  90-day  BP  values  and  predictors  of  90-day  BP  control  by  ECVRD  status.
Patients  with  ECVRD  Patients  without  ECVRD
Uncontrolled Uncontrolled
SBP  DBP  SBP  DBP  BP  SBP  DBP  SBP  DBP  BP
Patient-level  factors
Patient  age  ↑  ↑  ↑  ↓  ↑  ↓
Lives  alone  ↑
Obesity  ↑  ↑
Lack  of  regular  physical  exercise  ↑  ↑  ↑
Diabetes ↑ ↑  ↑  ↑  ↑  ↑  ↑
Family  history  of  premature
cardiovascular  disease
↑
Days  since  most  recent  BP  measurement ↑
C-reactive  protein  ≥  1  mg/dL  ↓
Highly-vulnerable  patient  cluster  ↑  ↑  ↑  ↑  ↑  ↑  ↑  ↑  ↑  ↑
Valsartan  80  mga ↓
Concomitant  ACE  inhibitor  ↑
Concomitant  ß-adrenergic  blocker  ↑  ↑  ↑  ↑  ↑
Non-adherent  days  in  the  past  4  weeks  ↑  ↑  ↑  ↑  ↑  ↑  ↑
Physician-level  factors
GP:  years  in  practice  ↑  ↑  ↑  ↑
GP:  hypertension  patients  seen  in  past
12  months
↓ ↓
GP:  median  duration  of  ﬁrst  visit  for
newly-diagnosed  hypertensive  patient
↑ ↑
GP:  median  duration  of  visits  for
antihypertensive  medication  titration
↑ ↑
GP:  mean  number  of  visits  during  ﬁrst  3
months  to  achieve  BP  control
↓
GP: number  of  BPG-concordant  practices  ↓  ↓  ↓  ↓  ↓  ↓
ACE: angiotensin-converting enzyme; BP: blood pressure; BPG: best practice guidelines; DBP: mean sitting diastolic blood pressure;
ECVRD: established cardiovascular/renal disease; GP: general practitioner; SBP: mean sitting systolic blood pressure.
a Compared to higher doses of Valsartan.
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Cf  the  medication  regimen  and  our  ﬁndings  conﬁrm  this,  in
articular  among  patients  with  ECVRD  [25].
Focusing  on  these  three  categories  of  determinants  of
P  outcomes  may  go  a  long  way  towards  overcoming  the
hypertension  paradox’  identiﬁed  by  Chobanian  [26], which
tates  that  despite  therapeutic  advances,  rates  of  uncon-
rolled  BP  keep  rising.  Our  studies  continue  to  underscore
he  inﬂuence  of  clinicians  in  successful  hypertension  man-
gement  and  this  may  be  an  integral  part  of  the  solution
o  the  hypertension  paradox  [16]. Physician-level  factors
mproved  BP  outcomes  in  general  but  especially  among
atients  with  ECVRD.  Managing  hypertension  in  congruence
ith  evidence-based  guidelines  is  critical,  as  is  exposure
o  a  high  volume  of  patients  with  hypertension.  Yet,  so  is
hysician  vigilance  —  although  this  was  not  demonstrated
irectly  but,  as  in  our  prior  studies,  paradoxically,  in  terms
f  number,  type  and  duration  of  visits  and  interval  of  BP
easurement  [16]. On  the  other  hand,  how  long  one  has
een  practicing  tends  to  lead  to  poorer  BP  outcomes  [16,25].
ence,  it  is  not  surprising  that  up  to  28.1%  of  BP  outcomes
ere  attributable  to  the  treating  physician,  conﬁrming  sim-
lar  proportions  observed  in  other  analyses  [16].
W
u
a
pThe limitations  of  the  PREVIEW  study,  its  subanalyses  and
elated  studies  have  been  identiﬁed  elsewhere  [13,16,27],
s  have  directions  for  future  research.  Limitations  include
he  study  being  conducted  in  only  one  country,  not  being
opulation-based,  focusing  only  on  valsartan  and  not  other
RBs  and  not  being  an  effectiveness  randomized  controlled
rial  but  an  effectiveness  observational  study.  The  subanal-
ses  here  employed  a  post  hoc-deﬁned  binary  measure  of
CVRD;  future  studies  are  needed  to  evaluate  the  role  of  an
 priori  operationalized  ECVRD  gradient  on  BP  outcomes  fol-
owing  antihypertensive  treatment.  In  this  regard,  it  might
e  helpful  to  examine  the  interaction  of  established  cardio-
ascular  and  established  renal  disease,  not  just  as  singular
r  joint  presences.
onclusione  examined  the  multilevel  determinants  of  90-day  BP  val-
es  and  control  in  1107  hypertensive  patients  with  ECVRD
nd  2087  without  ECVRD  being  treated  with  valsartan  as
art  of  the  Belgian  PREVIEW  study.  A  greater  proportion
utco
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[Valsartan,  cardiovascular/renal  disease  and  blood  pressure  o
of  patients  without  ECVRD  had  controlled  SBP  and  DBP
at  90  days  compared  with  patients  with  ECVRD.  Many  of
the  patient-  and  physician-level  determinants  of  BP  by
ECVRD  subpopulation  are  amenable  to  intervention  and  the
remainder  can  serve  as  warning  signs  that  patients  may
remain  vulnerable  to  poor  outcomes  associated  with  subop-
timal  BP  control.  ECVRD  patients  present  with  differential
characteristics,  conditions  and  determinants  that  mandate
individualized  attention  to  complement  general  evidence-
based  antihypertensive  treatment.
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